<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072773</url>
  </required_header>
  <id_info>
    <org_study_id>MC0985</org_study_id>
    <secondary_id>NCI-2009-01564</secondary_id>
    <secondary_id>09-005736</secondary_id>
    <secondary_id>MC0985</secondary_id>
    <secondary_id>X05306</secondary_id>
    <nct_id>NCT01072773</nct_id>
  </id_info>
  <brief_title>Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis</brief_title>
  <official_title>Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and
      dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Giving bortezomib together with combination
      chemotherapy may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving bortezomib, cyclophosphamide, and
      dexamethasone together works in treating patients with primary systemic light chain
      amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To assess the confirmed hematologic response rate of the combination of bortezomib,
      cyclophosphamide and dexamethasone in patients with primary systemic amyloidosis.

      SECONDARY OBJECTIVES:

      I. Organ response rate of the bortezomib, cyclophosphamide and dexamethasone combination.

      II. Severity and frequency of adverse events associated with bortezomib, cyclophosphamide and
      dexamethasone treatment in patients with primary systemic amyloidosis.

      III. Time to progression.

      IV. Survival.

      OUTLINE: Patients receive bortezomib IV on days 1, 8, and 15 and oral cyclophosphamide and
      oral dexamethasone once daily on days 1, 8, 15, and 22. Treatment repeats every 28 days for
      up to 12 courses in the absence of disease progression or unacceptable toxicity. After
      completion of study treatment, patients are followed every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Confirmed Hematologic Response</measure>
    <time_frame>Duration of treatment (up to 12 cycles/months)</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations during treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;=100 mg per 24 hours.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or Urine M-Component &gt;=90% reduction or &lt;200 mg per 24 hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Related Adverse Events.</measure>
    <time_frame>Duration on treatment (up to 12 cycles/months)</time_frame>
    <description>Adverse events (AE) that are classified as either possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0). The maximum grade for each type of AE will be recorded for each patient. Grade refers to the severity of the AE.
Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE, Grade 5: Death related AE
Adverse events will be assessed using NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Organ Response.</measure>
    <time_frame>Duration on treatment (up to 12 cycles/months)</time_frame>
    <description>The number of patients that acheived a response in an affected organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Duration of Study (up to 5 years)</time_frame>
    <description>Survival time is defined as the time from registration to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Duration of Study (up to 5 years)</time_frame>
    <description>Time to disease progression is defined as the time from registration to the earliest date of documented disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Duration of Study (up to 5 years)</time_frame>
    <description>Duration of response will be calculated from the date of first evidence of response until the date of progression in the subset of patients with confirmed hematologic responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Primary Systemic Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Bortez/Cyc/Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.3 mg/m^2, by IV on days 1, 8 and 15 every 28 days</description>
    <arm_group_label>Bortez/Cyc/Dex</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>300 mg/m^2, orally, on days 1, 8, 15 &amp; 22 every 28 days.</description>
    <arm_group_label>Bortez/Cyc/Dex</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
    <other_name>Enduxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>40 mg, orally, on days 1, 8, 15 &amp; 22 every 28 days</description>
    <arm_group_label>Bortez/Cyc/Dex</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decaspray</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy
             of green birefringent material in Congo red-stained tissue specimens

          -  Measurable disease of amyloid light chain amyloidosis as defined by at least ONE of
             the following: serum monoclonal protein &gt;= 1.0 g by protein electrophoresis, &gt; 200 mg
             of monoclonal protein in the urine on 24 hour electrophoresis, serum free light-chain
             &gt;= 7.5 mg/dL with an abnormal kappa:lambda ratio

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2

          -  Absolute neutrophil count &gt;= 1000/uL

          -  Platelet &gt;= 75000/uL

          -  Total bilirubin &lt; 3.0 mg/dL

          -  Aspartate aminotransferase (AST) =&lt; 3 x upper limit of normal (ULN)

          -  Creatinine clearance &gt;= 30ml/min

          -  Women of childbearing potential should have a negative serum or urine pregnancy test
             done =&lt; 7 days prior to registration, and should be willing to use an acceptable
             method of birth control (i.e., a hormonal contraceptive, intra-uterine device,
             diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of
             the study

          -  Male subject agrees to use an acceptable method for contraception for the duration of
             the study

          -  Previously treated amyloidosis; no limit to prior therapy provided there is adequate
             residual organ function

          -  Symptomatic organ involvement (heart, kidney, liver/GI tract, peripheral nervous
             system or soft tissue); carpal tunnel syndrome skin purpura, or the presence of
             vascular amyloid on a bone marrow biopsy alone are not sufficient to meet criteria for
             &quot;symptomatic organ involvement&quot;

          -  Renal involvement is defined as proteinuria (predominantly albumin) &gt; 0.5 g/day in a
             24- hour urine collection

          -  Cardiac involvement is defined as the presence of a mean left ventricular wall
             thickness on echocardiogram greater than 12 mm in the absence of a history of
             hypertension or valvular heart disease, or in the presence of unexplained low voltage
             (&lt; 0.5 mV) on the electrocardiogram

          -  Hepatic involvement is defined as hepatomegaly (&gt;= 2 cm below costal margin) on
             physical exam or an alkaline phosphatase &gt; 1.5 x ULN

          -  Peripheral nerve involvement is defined based on clinical history or abnormal sensory
             and/or motor findings on neurologic exam

          -  Autonomic nerve involvement is defined as orthostasis, symptoms of nausea or
             dysgeusia, gastric atony by gastric emptying scan, diarrhea or constipation

          -  Soft tissue and lymphatic involvement may be ascertained based on classic physical
             exam findings (macroglossia, shoulder pad sign, raccoon eyes, carpal tunnel syndrome,
             synovial enlargement, firm enlarged lymph nodes) or biopsy

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by subject any time without prejudice to future medical care

          -  Willingness to return to Mayo Clinic enrolling institution for follow-up

        Exclusion Criteria:

          -  Melphalan or other myelosuppressive agents =&lt; 3 weeks prior to registration;
             non-myelosuppressive agents like thalidomide, or high dose corticosteroids &lt;= 1week
             prior to registration

          -  Concurrent use of corticosteroids, but patients may be on chronic steroids (maximum
             dose 20 mg/day prednisone equivalent) if they are being given for disorders other than
             amyloid, i.e., adrenal insufficiency, rheumatoid arthritis, etc

          -  Any of the following because this study involves an agent whose genotoxic, mutagenic
             and teratogenic effects on the developing fetus and newborn are unknown: pregnant
             women and nursing women

          -  Other active malignancy =&lt; 2 years prior to registration; EXCEPTIONS: Nonmelanotic
             skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior
             malignancy, they must not be receiving any specific treatment for their cancer

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens including psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Known to be HIV positive

          -  Receiving any other investigational agent which would be considered as a treatment for
             the primary neoplasm

          -  Clinically overt multiple myeloma (monoclonal Bone Marrow Plasma Count &gt; 30%), and at
             least one of the following: bone lesions or hypercalcemia

          -  History of myocardial infarction =&lt; 6 months, or requiring use of ongoing maintenance
             drug therapy for life-threatening ventricular arrhythmias

          -  Grade 3 sensory or grade 1 painful peripheral neuropathy

          -  Known hypersensitivity to bortezomib, boron or mannitol

          -  Cardiac syncope, uncompensated New York Heart Association (NYHA) Class 3 or 4
             congestive heart failure or troponin T &gt; 0.1 ng/mL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaji Kumar, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <results_first_submitted>November 7, 2012</results_first_submitted>
  <results_first_submitted_qc>November 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2012</results_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bortez/Cyc/Dex</title>
          <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortez/Cyc/Dex</title>
          <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="67" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Treatment</title>
          <description>Number of previous regimens used for the treatment of amyloidosis. There is no limit to the number of prior therapies provided there is adequate residual organ function.</description>
          <units>Prior Treatments</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Confirmed Hematologic Response</title>
        <description>Response that was confirmed on 2 consecutive evaluations during treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;=100 mg per 24 hours.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or Urine M-Component &gt;=90% reduction or &lt;200 mg per 24 hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
        <time_frame>Duration of treatment (up to 12 cycles/months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortez/Cyc/Dex</title>
            <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Confirmed Hematologic Response</title>
          <description>Response that was confirmed on 2 consecutive evaluations during treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;=100 mg per 24 hours.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or Urine M-Component &gt;=90% reduction or &lt;200 mg per 24 hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good Partial Response (VGPR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Related Adverse Events.</title>
        <description>Adverse events (AE) that are classified as either possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0). The maximum grade for each type of AE will be recorded for each patient. Grade refers to the severity of the AE.
Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE, Grade 5: Death related AE
Adverse events will be assessed using NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.</description>
        <time_frame>Duration on treatment (up to 12 cycles/months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortez/Cyc/Dex</title>
            <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Related Adverse Events.</title>
          <description>Adverse events (AE) that are classified as either possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0). The maximum grade for each type of AE will be recorded for each patient. Grade refers to the severity of the AE.
Grade 1: Mild AE, Grade 2: Moderate AE, Grade 3: Severe AE, Grade 4: Life-threatening or disabling AE, Grade 5: Death related AE
Adverse events will be assessed using NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Organ Response.</title>
        <description>The number of patients that acheived a response in an affected organ.</description>
        <time_frame>Duration on treatment (up to 12 cycles/months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortez/Cyc/Dex</title>
            <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Organ Response.</title>
          <description>The number of patients that acheived a response in an affected organ.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Survival time is defined as the time from registration to death due to any cause.</description>
        <time_frame>Duration of Study (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortez/Cyc/Dex</title>
            <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival time is defined as the time from registration to death due to any cause.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.35" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time to disease progression is defined as the time from registration to the earliest date of documented disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death</description>
        <time_frame>Duration of Study (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortez/Cyc/Dex</title>
            <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to disease progression is defined as the time from registration to the earliest date of documented disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.35" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response will be calculated from the date of first evidence of response until the date of progression in the subset of patients with confirmed hematologic responses.</description>
        <time_frame>Duration of Study (up to 5 years)</time_frame>
        <population>Neither participant achieved a response. Therefore, no duration of response calculation was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bortez/Cyc/Dex</title>
            <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response will be calculated from the date of first evidence of response until the date of progression in the subset of patients with confirmed hematologic responses.</description>
          <population>Neither participant achieved a response. Therefore, no duration of response calculation was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bortez/Cyc/Dex</title>
          <description>Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shaji Kumar</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>kumar.shaji@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

